vs
Revvity（RVTY）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs -3.1%，领先15.9%），Revvity同比增速更快（5.9% vs -11.9%），Revvity自由现金流更多（$161.8M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 9.0%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
RVTY vs RXO — 直观对比
营收规模更大
RXO
是对方的1.9倍
$772.1M
营收增速更快
RVTY
高出17.7%
-11.9%
净利率更高
RVTY
高出15.9%
-3.1%
自由现金流更多
RVTY
多$170.8M
$-9.0M
两年增速更快
RXO
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $1.5B |
| 净利润 | $98.4M | $-46.0M |
| 毛利率 | — | — |
| 营业利润率 | 14.5% | -2.9% |
| 净利率 | 12.7% | -3.1% |
| 营收同比 | 5.9% | -11.9% |
| 净利润同比 | 3.9% | -84.0% |
| 每股收益（稀释后） | $0.86 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYRXO
| Q4 25 | $772.1M | $1.5B | ||
| Q3 25 | $698.9M | $1.4B | ||
| Q2 25 | $720.3M | $1.4B | ||
| Q1 25 | $664.8M | $1.4B | ||
| Q4 24 | $729.4M | $1.7B | ||
| Q3 24 | $684.0M | $1.0B | ||
| Q2 24 | $691.7M | $930.0M | ||
| Q1 24 | $649.9M | $913.0M |
净利润RVTYRXO
| Q4 25 | $98.4M | $-46.0M | ||
| Q3 25 | $46.7M | $-14.0M | ||
| Q2 25 | $53.9M | $-9.0M | ||
| Q1 25 | $42.2M | $-31.0M | ||
| Q4 24 | $94.6M | $-25.0M | ||
| Q3 24 | $94.4M | $-243.0M | ||
| Q2 24 | $55.4M | $-7.0M | ||
| Q1 24 | $26.0M | $-15.0M |
毛利率RVTYRXO
| Q4 25 | — | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 54.5% | — | ||
| Q1 25 | 56.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 54.6% | — |
营业利润率RVTYRXO
| Q4 25 | 14.5% | -2.9% | ||
| Q3 25 | 11.7% | -0.5% | ||
| Q2 25 | 12.6% | — | ||
| Q1 25 | 10.9% | -2.1% | ||
| Q4 24 | 16.3% | -1.4% | ||
| Q3 24 | 14.3% | -1.9% | ||
| Q2 24 | 12.4% | — | ||
| Q1 24 | 6.8% | -1.3% |
净利率RVTYRXO
| Q4 25 | 12.7% | -3.1% | ||
| Q3 25 | 6.7% | -1.0% | ||
| Q2 25 | 7.5% | -0.6% | ||
| Q1 25 | 6.4% | -2.2% | ||
| Q4 24 | 13.0% | -1.5% | ||
| Q3 24 | 13.8% | -23.4% | ||
| Q2 24 | 8.0% | -0.8% | ||
| Q1 24 | 4.0% | -1.6% |
每股收益（稀释后）RVTYRXO
| Q4 25 | $0.86 | $-0.28 | ||
| Q3 25 | $0.40 | $-0.08 | ||
| Q2 25 | $0.46 | $-0.05 | ||
| Q1 25 | $0.35 | $-0.18 | ||
| Q4 24 | $0.77 | $-0.17 | ||
| Q3 24 | $0.77 | $-1.81 | ||
| Q2 24 | $0.45 | $-0.06 | ||
| Q1 24 | $0.21 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $17.0M |
| 总债务越低越好 | — | $387.0M |
| 股东权益账面价值 | $7.3B | $1.5B |
| 总资产 | $12.2B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资RVTYRXO
| Q4 25 | $919.9M | $17.0M | ||
| Q3 25 | $931.4M | $25.0M | ||
| Q2 25 | $991.8M | $18.0M | ||
| Q1 25 | $1.1B | $16.0M | ||
| Q4 24 | $1.2B | $35.0M | ||
| Q3 24 | $1.2B | $55.0M | ||
| Q2 24 | $2.0B | $7.0M | ||
| Q1 24 | $1.7B | $7.0M |
总债务RVTYRXO
| Q4 25 | — | $387.0M | ||
| Q3 25 | — | $387.0M | ||
| Q2 25 | — | $387.0M | ||
| Q1 25 | — | $387.0M | ||
| Q4 24 | — | $351.0M | ||
| Q3 24 | — | $352.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $351.0M |
股东权益RVTYRXO
| Q4 25 | $7.3B | $1.5B | ||
| Q3 25 | $7.4B | $1.6B | ||
| Q2 25 | $7.6B | $1.6B | ||
| Q1 25 | $7.6B | $1.6B | ||
| Q4 24 | $7.7B | $1.6B | ||
| Q3 24 | $7.9B | $1.7B | ||
| Q2 24 | $7.9B | $579.0M | ||
| Q1 24 | $7.8B | $582.0M |
总资产RVTYRXO
| Q4 25 | $12.2B | $3.3B | ||
| Q3 25 | $12.1B | $3.2B | ||
| Q2 25 | $12.4B | $3.2B | ||
| Q1 25 | $12.4B | $3.3B | ||
| Q4 24 | $12.4B | $3.4B | ||
| Q3 24 | $12.8B | $3.4B | ||
| Q2 24 | $13.4B | $1.8B | ||
| Q1 24 | $13.4B | $1.8B |
负债/权益比RVTYRXO
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $161.8M | $-9.0M |
| 自由现金流率自由现金流/营收 | 21.0% | -0.6% |
| 资本支出强度资本支出/营收 | 2.6% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.85× | — |
| 过去12个月自由现金流最近4个季度 | $509.4M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流RVTYRXO
| Q4 25 | $182.0M | $7.0M | ||
| Q3 25 | $138.5M | $23.0M | ||
| Q2 25 | $134.3M | $23.0M | ||
| Q1 25 | $128.2M | $-2.0M | ||
| Q4 24 | $174.2M | $-7.0M | ||
| Q3 24 | $147.9M | $-7.0M | ||
| Q2 24 | $158.6M | $-5.0M | ||
| Q1 24 | $147.6M | $7.0M |
自由现金流RVTYRXO
| Q4 25 | $161.8M | $-9.0M | ||
| Q3 25 | $120.0M | $9.0M | ||
| Q2 25 | $115.5M | $9.0M | ||
| Q1 25 | $112.2M | $-17.0M | ||
| Q4 24 | $149.8M | $-19.0M | ||
| Q3 24 | $125.6M | $-18.0M | ||
| Q2 24 | $136.6M | $-16.0M | ||
| Q1 24 | $129.7M | $-4.0M |
自由现金流率RVTYRXO
| Q4 25 | 21.0% | -0.6% | ||
| Q3 25 | 17.2% | 0.6% | ||
| Q2 25 | 16.0% | 0.6% | ||
| Q1 25 | 16.9% | -1.2% | ||
| Q4 24 | 20.5% | -1.1% | ||
| Q3 24 | 18.4% | -1.7% | ||
| Q2 24 | 19.7% | -1.7% | ||
| Q1 24 | 20.0% | -0.4% |
资本支出强度RVTYRXO
| Q4 25 | 2.6% | 1.1% | ||
| Q3 25 | 2.6% | 1.0% | ||
| Q2 25 | 2.6% | 1.0% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 3.4% | 0.7% | ||
| Q3 24 | 3.3% | 1.1% | ||
| Q2 24 | 3.2% | 1.2% | ||
| Q1 24 | 2.7% | 1.2% |
现金转化率RVTYRXO
| Q4 25 | 1.85× | — | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 2.49× | — | ||
| Q1 25 | 3.03× | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.57× | — | ||
| Q2 24 | 2.87× | — | ||
| Q1 24 | 5.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
